Sun Pharma Q3 FY25 Results: Net profit rises 24.1% YoY to Rs 3,219.6 crore, gross sales increase 10.5%

Sun Pharmaceutical Industries Limited has reported strong financial performance for the third quarter ending December 31, 2024 (Q3 FY25). The company recorded a 24.1% year-on-year (YoY) growth in adjusted net profit to Rs 3,219.6 crore, compared to Rs 2,523.8 crore in Q3 FY24. Gross sales for the quarter stood at Rs 13,436.9 crore, marking a 10.5% YoY increase.

Key highlights of Q3 FY25 consolidated financials:

• Gross sales: Rs 13,436.9 crore, up 10.5% YoY
• India formulation sales: Rs 4,300.4 crore, a 13.8% increase YoY
• US formulation sales: US$ 474 million, down 0.7% YoY
• Global Specialty sales: US$ 370 million, including US$ 45 million from milestones, growing 17.5% YoY
• Emerging markets sales: US$ 277 million, up 10.1% YoY
• Rest of World formulation sales: US$ 259 million, a 21% YoY growth
• EBITDA: Rs 4,009 crore, up 15.3% YoY, with an EBITDA margin of 29.3%
• R&D investments: Rs 845 crore in Q3 FY25, compared to Rs 824.5 crore YoY

The company also declared an interim dividend of Rs 10.50 per share for FY25, compared to Rs 8.50 in the previous fiscal year.

Segment-wise performance:

• India formulations: Recorded strong growth due to robust demand across therapeutic areas. The company also launched 12 new products during the quarter.
• US formulations: Sales were marginally lower, reflecting some challenges in pricing and product mix.
• Emerging markets and Rest of World (ROW): Both segments witnessed strong double-digit growth, with ROW sales accounting for 16% of total sales.
• API sales: External API sales grew 21.8% YoY to Rs 567.8 crore, supporting the company’s global formulation business.

Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, said, “Our performance reflects broad-based growth across key markets, particularly in India and emerging markets. We remain focused on our specialty business and R&D investments to sustain future growth.”